Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-02 CAR-T in R/R DLBCL
NCT04215016Phase 1Unknown
- Sponsor
- Fujian Medical University
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of A-02 in diffuse large B-cell lymphoma (DLBCL), sponsored by Fujian Medical University. Primary endpoint: Adverse Events at 12 months. Status: unknown.
02
Drugs
A-02
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04215016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215016.